Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies
暂无分享,去创建一个
Tadashi Nariai | Keiichi Oda | Kiichi Ishiwata | Kenji Ishii | Muneyuki Sakata | Jun Toyohara | K. Ishii | K. Oda | K. Ishiwata | T. Nariai | J. Toyohara | M. Sakata
[1] K. Någren,et al. Human Dosimetry of Carbon-11 Labeled N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide Extrapolated from Whole-body Distribution Kinetics and Radiometabolism in Rats , 2010, Molecular Imaging and Biology.
[2] Robert B. Innis,et al. Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[3] H. Thierens,et al. Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] Icrp. ICRP Publication 60: 1990 Recommendations of the International Commission on Radiological Protection , 1991 .
[5] H. Herzog,et al. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-l-tyrosine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[6] B F Hutton,et al. Simultaneous emission and transmission measurements for attenuation correction in whole-body PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] G. Firnau,et al. Estimation of the radiation dose in man due to 6-[18F]fluoro-L-dopa. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] K. Hashimoto,et al. Biodistribution and radiation dosimetry of the α7 nicotinic acetylcholine receptor ligand [11C]CHIBA-1001 in humans. , 2011, Nuclear medicine and biology.
[9] D. J. Valentin. 3. Recalculated dose data for 19 frequently used radiopharmaceuticals from ICRP Publication 53 , 1998 .
[10] Yuichi Kimura,et al. Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography , 2003, Annals of nuclear medicine.
[11] R. Dannals,et al. PET imaging of brain acetylcholinesterase using [11C]CP‐126,998, a brain selective enzyme inhibitor , 2002, Synapse.
[12] Michael G Stabin,et al. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] S. Huskey,et al. Species differences in N-glucuronidation. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[14] M. Senda,et al. 11C-labeled KF18446: a potential central nervous system adenosine A2a receptor ligand. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] H. Watabe,et al. Absorbed dose estimates in positron emission tomography studies based on the administration of 18F-labeled radiopharmaceuticals. , 1991, Journal of radiation research.
[16] M. Senda,et al. Preclinical evaluation of [11C]SA4503: radiation dosimetry,in vivo selectivity and PET imaging of sigma1 receptors in the cat brain , 2000, Annals of nuclear medicine.
[17] H. Minn,et al. Biodistribution and radiation dosimetry of [11C]choline: a comparison between rat and human data , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[18] Jan Passchier,et al. Radiation dose estimates for carbon-11-labelled PET tracers. , 2012, Nuclear medicine and biology.
[19] J. Hirvonen,et al. Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[20] Ming-fang Wang,et al. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-L-tyrosine as oncologic PET tracer. , 2003, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[21] Masatoshi Itoh,et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-d- glucose using whole-body positron emission tomography and magnetic resonance imaging , 1998, European Journal of Nuclear Medicine.
[22] W. Beierwaltes,et al. Radiation Dosimetry of 131I-19-Iodocholesterol: The Pitfalls of Using Tissue Concentration Data—Reply , 1975 .
[23] J. Lin,et al. Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[24] A. D. Roberts,et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] K. Hashimoto,et al. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography , 2009, Annals of nuclear medicine.
[26] Kazutoshi Suzuki,et al. Feasibility studies of 4'-[methyl-(11)C]thiothymidine as a tumor proliferation imaging agent in mice. , 2008, Nuclear medicine and biology.
[27] Tadashi Nariai,et al. Preclinical studies on [11C]MPDX for mapping adenosine A1 receptors by positron emission tomography , 2002, Annals of nuclear medicine.
[28] K. Ishii,et al. Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: A Pilot Study , 2011, The Journal of Nuclear Medicine.
[29] K. Ishiwata,et al. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-D,L-phenylalanine: a target compound for PET and boron neutron capture therapy. , 1991, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[30] Kiichi Ishiwata,et al. In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors , 2000 .
[31] H Orihara,et al. Performance evaluation of a large axial field-of-view PET scanner: SET-2400W , 1997, Annals of nuclear medicine.
[32] M. Senda,et al. Electrophilic synthesis of 6-[18F]fluoro-L-DOPA : use of 4-O-pivaloyl-L-DOPA as a suitable precursor for routine production , 1993 .